Converging data indicate that the immune system is able to recognize
cancer epitopes as non-self and mount an immune reaction that may erase, or temporarily block,
tumor growth. The immune pressure supports the amplification of immune resistant
tumor clones, creating an immune suppressive environment that leads to the formation of a clinically relevant
tumor. These general observations also apply to
brain tumors and specifically to
gliomas.
Cancer immunotherapy strategies are aimed at reverting such immune suppression. Two approaches are already used in the clinics. The first one,
peptide immunotherapy, has been oriented to the most aggressive
glioma,
glioblastoma (GBM) where, in the context of EGFR (
epidermal growth factor receptor) amplification, a large deletion arises and creates a novel,
cancer-specific
antigen,
EGFRvIII. The second one is dendritic cell
immunotherapy. Dendritic cells are potent antigen presenting cells that can be pulsed with autologous
tumor lysate or
peptide pp65 from cytomegalovirus (CMV) that is present in GBM but not in normal brain. Antigen presentation by dendritic cells is bolstered by preconditioning their injection site with the
tetanus/
diphtheria toxoid. The third approach is adoptive
cell therapy (ACT) in which
tumor-specific T cells can be amplified ex vivo and subsequently re-injected to the patient to lyse cells expressing
tumor antigens, increasing survival durably in a fraction of
melanoma patients. ACT may also be based on T cell transduction of
tumor specific receptors or
chimeric antigen receptors (CARs). CARs are powerful tools for
immunotherapy but off-target toxicity may be an issue as they do not request MHC presentation for activation. Upcoming clinical trial results will clarify the most effective direction for
cancer immunotherapy in
gliomas and other
cancers with poor prognosis.